A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Phase 1 – testing safety in a small group of people
Conditions:
Solid Tumor
Sponsor: Genentech, Inc.
trial.available_in:
БГ
Overview
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.
Who can participate
Inclusion Criteria:
* Histologically documented advanced or metastatic solid tumor with KRAS G12D mutation
* Agreement to adhere to the contraception requirements described in the protocol for participants of childbearing potential and participants who produce sperm
Exclusion criteria:
* Malabsorption or other condition that would interfere with enteral absorption
* Active brain metastases
* Clinically significant cardiovascular dysfunction or liver disease
Locations
8
Australia (1)
St Vincent's Hospital Sydney
Darlinghurst , New South Wales
Canada (1)
British Columbia Cancer Agency
Vancouver , British Columbia
Israel (1)
Rambam Health Care Campus
Haifa
Singapore (1)
National University Hospital
Singapore
South Korea (1)
Seoul National University Bundang Hospital
Seongnam
Spain (1)
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
БГ